A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2017
At a glance
- Drugs PLX 73086 (Primary)
- Indications Giant cell tumour of tendon sheath; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Plexxikon
- 01 Aug 2017 Planned End Date changed from 1 Oct 2019 to 1 Apr 2018.
- 01 Aug 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Oct 2017.
- 01 Aug 2017 Status changed from recruiting to active, no longer recruiting.